|
|
Last Modified: 5/15/2008  First Published: 7/23/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other, Pharmaceutical / Industry
|
|
|
|
OCTO-ASPECT RADCLIFFE-32, ZENECA-RADCLIFFE-32, EUDRACT-2004-003836-77, ISRCTN85156844, EU-20628, NCT00357682
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Prevention
|
|
|
|
Active
|
|
|
|
40 to 75
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
COLO CP-01-US NCT00486512
|
|
|
|
|
|
|
|
Last Modified: 12/17/2008  First Published: 11/28/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
21 and over
|
|
|
|
Other
|
|
|
|
SINGAPORE-ICR-02 ICR-02, SINGAPORE-ASCOLT, NCT00565708, SINGAPORE-07-32-LGI
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
05-0427 NCT00263211
|
|
|
|
|
|
|
|
Last Modified: 10/20/2008  First Published: 5/11/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
MAYO-MAY04-4-01 MAY04-4-01, NCT00474903
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
RV-PI-0103 07/04, NCT00482261
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 to 80
|
|
|
|
Other
|
|
|
|
UCI 07-47 NCT00578721
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
2007-0266 NCT00790452
|
|
|
|
|
|
|
|
Last Modified: 10/12/2007  First Published: 4/23/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Active
|
|
|
|
Under 75
|
|
|
|
NCI
|
|
|
|
NU-NWU04-2-03 NWU04-2-03, NCT00468910
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Prevention
|
|
|
|
Active
|
|
|
|
45 to 74
|
|
|
|
Other
|
|
|
|
05-7956-01 NCT00234299
|
|
|
|